, Volume 191, Issue 4, pp 1023–1026 | Cite as

Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up

  • Marius K. Nickel
  • Thomas H. Loew
  • Francisco Pedrosa Gil
Original Investigation



Only one controlled trial is known that employed aripiprazole for patients with borderline personality disorder (BPD). This 8-week trial found significant changes on most scales of the symptom checklist (SCL-90-R), Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS), and on all scales of the state–trait anger expression inventory (STAXI).

Objectives, materials, and methods

To assess the long-term effectiveness of aripiprazole with multifaceted borderline symptomology, this 18-month follow-up observation with biannual testing was carried out with the same patients from the previous trial (treated with 15-mg aripiprazole daily, n = 26, 21 female and 5 male patients; previous placebo group, n = 26, 22 female and 4 male patients).


According to the intent-to-treat principle, significant changes on all scales of the SCL-90-R, HDRS, HARS, and STAXI were observed in the aripiprazole-treated subjects after 18 months.


Aripiprazole appears to be an effective and relatively safe agent in the long-term treatment of patients with BPD.


Borderline personality disorder Aripiprazole Hamilton depression rating scale 



We are grateful to Ann Marie Ackermann, JD, for translating and editing this article. The study was not funded.


  1. Briley M, Moret C (1993) Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 16:387–400PubMedCrossRefGoogle Scholar
  2. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005) The use of aripiprazole in obsessive–compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66:49–51PubMedCrossRefGoogle Scholar
  3. Franke GH (2002) SCL-90-R: Symptom-Checkliste von L.R. Derogatis. Goettingen, BeltzGoogle Scholar
  4. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMedGoogle Scholar
  5. Hamilton M (1976) Development of a rating scale; for primary depressive illness. Br J Soc Clin Psychol 6:278–296Google Scholar
  6. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology 182:220–231PubMedCrossRefGoogle Scholar
  7. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325–337PubMedCrossRefGoogle Scholar
  8. Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160:1651–1658PubMedCrossRefGoogle Scholar
  9. Jagadheesan K, Muirhead D (2004) Aripiprazole for acute mania. Am J Psychiatry 161:1926–1927PubMedCrossRefGoogle Scholar
  10. Mobascher A, Mobascher J, Schlemper V, Winterer G, Malevani J (2006) Aripiprazole pharmacotherapy of borderline personality disorder. Phaarmacopsychiatry 39:111–112CrossRefGoogle Scholar
  11. Nickel M, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, C Egger, Anvar J, Rother W, Loew T, Kaplan P (2006) Aripiprazole in treatment of borderline patients: a double-blind, placebo-controlled study. Am J Psychiatry 163:833–838PubMedCrossRefGoogle Scholar
  12. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E. Stringfellow J, Ingenito G, Marder SR (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690PubMedCrossRefGoogle Scholar
  13. Schwenkmezger, P, Hodapp, V, Spielberger, CD (1992) The State-Trait Anger Expression Inventory. Goettingen, BernGoogle Scholar
  14. Stevens J (1992) Applied multivariate statistics for the social sciences. Erlbaum, New JerseyGoogle Scholar
  15. Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J (2003) Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Personal Disord 17:233–242PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Marius K. Nickel
    • 1
    • 2
  • Thomas H. Loew
    • 3
  • Francisco Pedrosa Gil
    • 4
  1. 1.Clinic for Psychosomatic Medicine and PsychotherapyMedical University of GrazBad AusseeAustria
  2. 2.University Clinic for Psychiatry 1, PMUSalzburgAustria
  3. 3.Department of Psychosomatic MedicineUniversity ClinicRegensburgGermany
  4. 4.Psychosomatic Outpatient ClinicUniversity Medicine Clinic, LMUMunichGermany

Personalised recommendations